UGT2B10 CRISPR Activation Plasmid (h): sc-404210-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UGT2B10 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- UGT2B10 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by UGT2B10 CRISPR Activation Plasmid (h) and UGT2B10 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the UGT2B10 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UGT2B10 CRISPR Activation Plasmid (h) | sc-404210-ACT | 20 µg | $397.00 |
UGT2B10 encodes a human UDP-glucuronosyltransferase that catalyzes glucuronidation of endogenous and xenobiotic substrates, increasing their solubility for clearance through phase II metabolism. This ER-associated enzyme contributes to hepatic and extrahepatic detoxification networks that interface with oxidative stress responses and drug-handling pathways. Variation in UGT2B10 expression or activity has been linked to inter-individual differences in metabolism of select amines and other compounds, shaping exposure profiles and biomarker readouts. As a result, UGT2B10 is frequently studied in pharmacogenomics, chemical biology, and models of liver function and metabolic homeostasis.
UGT2B10 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous UGT2B10 expression without altering the underlying DNA sequence.
UGT2B10 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the UGT2B10 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the UGT2B10 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous UGT2B10 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native UGT2B10 locus and enabling the study of UGT2B10-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of UGT2B10 pathway restoration in tumor cells with silenced or reduced UGT2B10 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.